Class of Stock [Axis] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Customer [Axis] Large medical practice group and distributor [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Another large medical practice group and distributor [Member] Large distributor [Member] Another large distributor [Member] Two Individual Medical Practices [Member] Antidilutive Securities [Axis] Common shares issuable upon the exercise of options and warrants [Member] Common Shares Unissued Shares Of Restricted Stock [Member] Convertible Debt Securities [Member] Common shares issuable upon the future payments [Member] Long-Lived Asset, Class [Axis] Finance lease equipment [Member] Manufacturing equipment [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Sales Representative Agreement [Member] Lease Agreement [Member] Legal Entity [Axis] Management Services Organization [Member] Transaction Type [Axis] Sales Agreement [Member] Long-Term Debt, Type [Axis] Convertible promissory notes [Member] Plan Name [Axis] 2021 Plan [Member] Subscription agreement [Member] Counterparty Name [Axis] Investor [Member] Eight Investors [Member] Consulting Agreement [Member] Consultant [Member] 2021 Incentive Stock Plan [Member] Employee [Member] Title and Position [Axis] Chief Executive Officer [Member] Ian Bothwell [Member] Chief Medical Officer [Member] Dr. George Shapiro [Member] Greyt Ventures, LLC [Member] Employment Agreement [Member] Dr. Kisiday [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Award Type [Axis] Restricted Stock Awards [Member] Unvested restricted stock [Member] Equity Option [Member] Employees [Member] Warrant [Member] Supply Agreement [Member] Related and Nonrelated Parties [Axis] Howard Golub [Member] Two Investors [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current Assets Cash Accounts receivable, net of allowance for bad debts Prepaid expenses Inventories Total Current Assets Property and equipment, net Security deposit TOTAL ASSETS LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY (DEFICIT) Current Liabilities Accounts payable and accrued expenses Finance lease obligations Convertible promissory note, net of debt discount of $3,000 and $7,000 Obligation to repurchase shares Deferred revenue Total Current Liabilities Long term finance lease obligations Total Liabilities Commitments and contingencies Shares Subject To Possible Redemption Preferred stock value Stockholders’ Equity (Deficit) Common stock, $0.001 par value, 2,500,000,000 shares authorized; 7,787,441 and 6,747,441 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total Stockholders’ Equity (Deficit) TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY (DEFICIT) Debt discount net Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues (includes sales to related parties of approximately $30,000, $43,000, $30,000, and $75,000, respectively) Cost of revenues Gross profit General and administrative expenses Loss from operations Other income (expense) Gain on sale of Exotropin interests Interest expense Change in obligation to repurchase shares Other income Net loss Net loss per common share - basic Net loss per common share - diluted Weighted average number of common shares outstanding - basic Weighted average number of common shares outstanding - diluted Revenues from related parties Beginning balance, value Beginning balance, shares Sale of common stock Sale of common stock, shares Fair value of equity instruments issued for compensation: Fair value of shares issued as compensation Fair value of shares issued as compensation, shares Fair value of options issued Fair value of warrants issued Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense Amortization of OID and commitment fee discount – Promissory notes Stock-based compensation Gain on sale of Exotropin interests Change in obligation to repurchase shares Changes in operating assets and liabilities: Accounts receivable, net of allowance for bad debts Other receivable Prepaid expenses Inventories Accounts payable and accrued expenses Security deposits Deferred revenue Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of fixed assets Proceeds from sale of Exotropin interests Net cash provided by financing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from sale of common stock Payments on finance leases Net cash provided by (used in) financing activities Increase (decrease) in cash Cash at beginning of period Cash at end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for taxes Cash paid for interest NON-CASH INVESTING AND FINANCING TRANSACTIONS: Reduction in royalty payable through transfer of inventory Reduction in liability from sale of Exotropin interests Finance lease obligations Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES GOING CONCERN Inventory Disclosure [Abstract] INVENTORIES Property, Plant, and Equipment [Abstract] PROPERTY AND EQUIPMENT Equity In Non-marketable Securities Of Affiliated Entity EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY Finance Lease Obligations FINANCE LEASE OBLIGATIONS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes Payable NOTES PAYABLE Equity [Abstract] CAPITAL STOCK Stock Options And Warrants STOCK OPTIONS AND WARRANTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES SEGMENT INFORMATION Subsequent Events [Abstract] SUBSEQUENT EVENTS Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Terminated [Flag] Basis of Presentation Concentrations of Risk Use of Estimates Revenue Recognition Net Income (Loss) Per Common Share Stock-Based Compensation Research and Development Costs Fair Value of Financial Instruments Recently Issued Accounting Pronouncements Schedule of inventories Schedule of property and equipment Schedule of equity in non marketable securities Schedule of account payable and accrued expenses Schedule of notes payable Schedule of non vested share activity Schedule of stock options activity Schedule of assumptions Schedule of warrant activity Schedule of deferred revenue Schedule of other Income Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] FDIC insured amount Cash balances Revenues Concentration percentage Antidilutive securities excluded from computation of earnings per share Operating and finance lease obligation Net losses Cash from operating activities Accumulated deficit Stockholders' deficit Working capital deficit Raw materials and supplies Finished goods Total inventories Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Line Items] Property and equipment, gross Less: accumulated depreciation Total property and equipment, net Depreciation expense Equity in non-marketable securities Reserve on carrying value of investment in non-marketable securities Equity in non-marketable securities Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Aggregate cash consideration description Gain from sale of Exotropin interests Proceeds from sale of interests in Exotropin Reduction of previously recorded liabilities Payments for Commissions Payment to acquire Monthly payments Annual interest rate Estimated useful lives of leased equipment Finance lease obligations Finance lease obligations current Proceeds from Sale of Other Productive Assets Commissions Accrued payroll related liabilities Lab equipment and supplies payables Clinical trial and research payables Legal fees payable Other professional fees payable Interest payable Royalty payable Accrued commissions payable Construction payables Other payables and accrued expenses Total Accounts Payable and Accrued Expenses Convertible Promissory Note Unamortized discount Total Notes Payable Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Maturity date Interest rate Trading days Debt Instrument, Convertible, Conversion Price Discount Amortization of Debt Discount (Premium) Unamortized debt discount Number of shares converted Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of nonvested shares outstanding at beginning Fair value of nonvested shares outstanding at beginning Weighted- average grant date value, outstanding at beginning Non-vested shares granted Fair value of non-vested shares granted Weighted- average grant date value, non-vested shares granted Vested Fair value of vested shares Weighted- average grant date value, vested Expired/forfeited Fair value of expired/forfeited shares Weighted- average grant date value, expired/forfeited Number of nonvested shares, outstanding at end Fair value of nonvested shares, outstanding at end Weighted- average grant date value, outstanding at end Maximum aggregate number of shares Number of shares, outstanding Future issuance Shares available for issuance Number of common stock purchased Number of units sold Aggregate purchase price Number of shares reduced Shares description Shares issued Number of warrants purchased Number of shares awarded Share Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Option vested Unamortized compensation Number of shares, outstanding beginning balance Weighted-average exercise price, outstanding beginning balance Remaining contractual term (years), outstanding beginning balance Aggregate intrinsic value, outstanding beginning balance Number of shares, granted Weighted-average exercise price, granted Remaining contractual term (years), granted Aggregate intrinsic value, granted Number of shares, exercised Weighted-average exercise price, exercised Aggregate intrinsic value, exercised Number of shares, expired/forfeited Weighted-average exercise price, expired/forfeited Remaining contractual term (years), expired/forfeited Aggregate intrinsic value, expired/forfeited Number of shares outstanding ending balance Weighted-average exercise price outstanding ending balance Remaining contractual term (years) outstanding ending balance Aggregate intrinsic value outstanding ending balance Number of shares, exercisable Weighted-average exercise price, exercisable Remaining contractual term (years) outstanding, exercisable Aggregate intrinsic value, exercisable Exercise prices Expected dividends Expected volatility Risk free interest rate Expected life of options Aggregate intrinsic value, outstanding beginning balance Remaining contractual term, granted Number of shares, expired/forfeited Remaining contractual term (years) outstanding ending balance Aggregate intrinsic value, exercisable Option granted Aggregate fair value Options forfeited Stock compensation costs Unamortized compensation costs Number of common stock issued Warrants outstanding Warrants description Advances On Future Purchases Of Inventory Sales To Customers Not Yet Delivered Total Deferred Revenue Base salary Outstanding advances Settlement expenses Revenue Cost of goods sold Salaries & consulting fees Professional fees Commissions Marketing Stock based compensation Lab expenses Research & development Insurance Office expenses & other Other income (expenses), net Subsequent Event [Table] Subsequent Event [Line Items] Manufacturing Equipment [Member] Assets, Current Assets Liabilities, Current Liabilities Liabilities and Equity Gross Profit Operating Income (Loss) GainOnSaleOfExotropinInterests Interest Expense, Operating and Nonoperating ImpairmentOfNonmarketableSecuritiesInRelatedEntity Net Income (Loss) Attributable to Parent Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Other Receivables Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Deferred Revenue Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Property, Plant, and Equipment Cash Provided by (Used in) Investing Activity, Including Discontinued Operation PaymentsOnFinanceLease Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Marketable Securities, Noncurrent Finance Lease, Liability Long-Term Debt, Current Maturities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares FairValueOfNonvestedShares Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price FairValueOfVestedShares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value FairValueOfExpiredforfeitedShares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Cost of Product and Service Sold Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Professional Fees Commissions [Default Label] Marketing Expense Labor and Related Expense Research and Development Expense Insurance Tax Salary and Wage, Officer, Excluding Cost of Good and Service Sold